Palomar Health Partners with IKS Health for Holistic Healthcare Transformation

Palomar Health, a prominent healthcare system in North San Diego County, CA, has formed a multi-year partnership with IKS Health, a provider of technology-enabled healthcare solutions. This collaboration aims to harness advanced technology, including Gen AI, to support Palomar Health…

Read MorePalomar Health Partners with IKS Health for Holistic Healthcare Transformation

Tasso Survey: One in Three Patients Delay Blood Tests Due to Anxiety and Pain

Tasso, Inc., a leader in patient-centric blood collection solutions, recently surveyed over 600 U.S. adults aged 18 and older to explore their experiences and preferences regarding blood testing. The survey, titled Patient Preferences, Perceptions, and the Evolving Challenges of Ensuring…

Read MoreTasso Survey: One in Three Patients Delay Blood Tests Due to Anxiety and Pain

Luminate Health Dominates Direct-to-Consumer Lab Testing Market

Luminate Health, a leader in healthcare technology for the clinical laboratory and diagnostics sector, is achieving remarkable success with its Direct-to-Consumer (DTC) lab testing platform. This innovative service allows commercial and hospital laboratories to connect directly with patients, enhancing accessibility…

Read MoreLuminate Health Dominates Direct-to-Consumer Lab Testing Market

Prolucent Receives Strategic Investment from Northwell Holdings to Enhance Healthcare Workforce Management

Prolucent®, a leading provider of healthcare workforce optimization software and services, has announced a strategic investment from Northwell Holdings, the for-profit investment arm of Northwell Health, New York’s largest healthcare provider and private employer. This extended Series A funding follows…

Read MoreProlucent Receives Strategic Investment from Northwell Holdings to Enhance Healthcare Workforce Management

Glaukos Reports Positive Phase 3 Results for Epioxa™, Meeting Primary Efficacy Endpoint

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on innovative therapies for glaucoma, corneal disorders, and retinal diseases, has announced positive results from the second Phase 3 confirmatory trial for Epioxa™ (Epi-on). This next-generation corneal cross-linking…

Read MoreGlaukos Reports Positive Phase 3 Results for Epioxa™, Meeting Primary Efficacy Endpoint

PursueCare Launches FDA-Authorized RESET® and RESET-O® for Addiction Treatment

PursueCare, a leader in virtual addiction treatment, has announced the launch of RESET® and RESET-O®, the first FDA-authorized prescription digital therapeutics for substance use disorder (SUD) and opioid use disorder (OUD). These innovative app-based therapies offer a self-guided 12-week cognitive…

Read MorePursueCare Launches FDA-Authorized RESET® and RESET-O® for Addiction Treatment

bit.bio Secures Landmark Patent Defense for opti-ox™ Cell Programming Technology

bit.bio, a leader in synthetic biology focused on coding human cells for innovative therapies, has successfully defended its foundational European patent for opti-ox. This groundbreaking technology allows for the deterministic forward programming of pluripotent stem cells (PSCs), including induced pluripotent…

Read Morebit.bio Secures Landmark Patent Defense for opti-ox™ Cell Programming Technology

Celltrion Reveals Two-Year Post-Hoc Analysis Results for Subcutaneous Infliximab (CT-P13 SC) in IBD Treatment

Celltrion has announced the two-year results of dose escalation therapy with subcutaneous infliximab (CT-P13 SC) at the United European Gastroenterology (UEG) Week 2024 in Vienna. A post-hoc analysis of the LIBERTY-CD (Crohn’s disease) and LIBERTY-UC (ulcerative colitis) studies indicates that…

Read MoreCelltrion Reveals Two-Year Post-Hoc Analysis Results for Subcutaneous Infliximab (CT-P13 SC) in IBD Treatment